HUTCHMED's Orpathys-Tagrisso combination cuts death risk 32% in phase III lung cancer trial
HCM•HUTCHMED said the Orpathys-Tagrisso combination cut death risk by 32% in a phase III lung cancer trial. European and Japanese regulators accepted applications for review of the treatment combination.
1. Regulatory review
HUTCHMED announced that European and Japanese regulators accepted for review applications for Orpathys combined with Tagrisso for advanced non-small cell lung cancer with MET overexpression or amplification following progression on EGFR-targeted therapy. The Phase III SAFFRON trial showed improved survival and delayed disease progression versus platinum-based chemotherapy, with no new safety concerns.
